34 research outputs found
[89Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography
Purpose 111In (typically as [111In]oxinate3) is a gold standard
radiolabel for cell tracking in humans by scintigraphy. A long
half-life positron-emitting radiolabel to serve the same purpose
using positron emission tomography (PET) has long
been sought. We aimed to develop an 89Zr PET tracer for cell
labelling and compare it with [111In]oxinate3 single photon
emission computed tomography (SPECT).
Methods [89Zr]Oxinate4 was synthesised and its uptake and
efflux were measured in vitro in three cell lines and in human
leukocytes. The in vivo biodistribution of eGFP-5T33 murine
myeloma cells labelled using [89Zr]oxinate4 or [111In]oxinate3
was monitored for up to 14 days. 89Zr retention by living
radiolabelled eGFP-positive cells in vivo was monitored by
FACS sorting of liver, spleen and bone marrow cells followed
by gamma counting.
Results Zr labelling was effective in all cell types with yields
comparable with 111In labelling. Retention of 89Zr in cells
in vitro after 24 h was significantly better (range 71 to
>90 %) than 111In (43–52 %). eGFP-5T33 cells in vivo
showed the same early biodistribution whether labelled with
111In or 89Zr (initial pulmonary accumulation followed by
migration to liver, spleen and bone marrow), but later translocation
of radioactivity to kidneys was much greater for 111In.
In liver, spleen and bone marrow at least 92 % of 89Zr
remained associated with eGFP-positive cells after 7 days
in vivo.
Conclusion [89Zr]Oxinate4 offers a potential solution to the
emerging need for a long half-life PET tracer for cell tracking
in vivo and deserves further evaluation of its effects on survival
and behaviour of different cell types
PET Cell Tracking Using 18F-FLT is Not Limited by Local Reuptake of Free Radiotracer
Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2'-[(18)F]-fluoro-2'-deoxy-D-glucose ((18)F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3'-deoxy-3'-L-[(18)F]-fluorothymidine ((18)F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with (18)F-FDG or (18)F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free (18)F-FDG/(18)F-FLT or (18)F-FDG/(18)F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of (18)F-FLT from the injection site vs. (18)F-FDG (p ≤ 0.001), indicating local cellular uptake. Using (18)F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using (18)F-FLT labelling is an improved approach vs. (18)F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention